Wavelength Expands In India With Vanamali Deal
Acquires Majority Stake In Starting Materials And Intermediates Firm
Israel-based API specialist Wavelength Pharmaceuticals has expanded its operations in India by acquiring a majority stake in starting materials and intermediates provider Vanamali Organics.
You may also be interested in...
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
Sandoz is sponsoring a major hydroxychloroquine trial while other major industry players like Teva, Mylan, Apotex, Stada and Lupin are also accelerating efforts to fight the coronavirus crisis. Accord and Wavelength Pharma have stepped up their manufacturing to meet demand, as the AAM has cancelled its annual meeting.
Former head of Sun Pharma’s active pharmaceutical ingredients (APIs) operation Iftach Seri has been named as chief executive officer of Wavelength Pharmaceuticals, the APIs business that private investment firm SK Capital recently acquired from Perrigo for US$110 million (Generics bulletin, 1 December 2017, page 2).